News
MRK
127.00
+0.09%
0.12
Immutep reports promising efti/Keytruda data for head and neck cancer
Immutep reports promising efti/Keytruda data for head and neck cancer. The drug candidate is being tested in combination with Merck’s blockbuster cancer drug Keytruda. The company expects to release data on the primary endpoint in the first half of 2024.
Seeking Alpha · 5h ago
Pre-Market Earnings Report for April 25, 2024 : MRK, AZN, CAT, CMCSA, UNP, SPGI, HON, SNY, BMY, MO, NOC, VLO
NASDAQ · 5h ago
BUZZ-PREVIEW: Merck expected to report Q1 EPS, revenue increase
Merck & Co shares up 0.2% ahead of quarterly report due out before market open on Thursday. Merck expected to report Q1 EPS, revenue increase of 4.9% y/y. Wall St sees MRK reporting adj. EPS of $1.88 on revenue of $15.196. YTD shares in MRK up 17%.
Reuters · 7h ago
What to Watch in the Day Ahead - Thursday, April 25
Microsoft's revenue is expected to have grown 15% as AI investments drive gains in the tech industry. Data expected to show a slowdown in U.S. Economic growth in the first quarter. The Treasury Secretary Janet Yellen will be interviewed in New York. American Airlines expected to report a rise in first-quarter earnings.
Reuters · 7h ago
Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
NASDAQ · 9h ago
Why Australian Cancer Biotech Firm Immutep Stock Is Soaring On Wednesday?
Immutep Limited released preliminary topline results from a head and neck squamous cell carcinoma trial. The company is testing eftilagimod alpha in combination with Keytruda. The combination showed an overall response rate of 26.9% in 26 patients with negative PD-L1 expression.
Benzinga · 11h ago
4 Large Drug Stocks to Hold on to Amid Industry Challenges
NASDAQ · 11h ago
Merck Q1 Earnings Preview: Strong quarter expectations on the back of core products' growth
Merck is scheduled to announce Q1 earnings results on Thursday, April 25th. Analysts estimate a profit of $1.92 per share on revenue of $15.2B. The company is expected to have a strong quarter. MRK stock has gained 16.4% in the last 12 months.
Seeking Alpha · 11h ago
MRK Factor-Based Stock Analysis
NASDAQ · 12h ago
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
NASDAQ · 15h ago
Hanmi, Merck Collaborate To Evaluate BH3120 + Keytruda Combination In Metastatic Solid Tumors
NASDAQ · 23h ago
ImmunityBio: FDA Approval Gets Ball Rolling Towards Next Set Of Indications
ImmunityBio, Inc. Received FDA approval of its drug ANKTIVA for the treatment of patients with bladder cancer. The global bladder cancer market could reach $11.5 billion by 2032. Company also tends to evaluate the use of AN KTIVA towards other cancer indications.
Seeking Alpha · 1d ago
ImmunityBio Lights Up: Anktiva's FDA Nod Shakes Up Bladder Cancer Battle
ImmunityBio, Inc.'s Anktiva approved by FDA for bladder cancer. The drug faces tough competition from existing treatments and promising therapies in the pipeline. The company's stock jumped nearly 30% on the news of the approval. I believe ImmunityBio's $3 billion enterprise value is already baked in to the company's potential.
Seeking Alpha · 1d ago
Understanding Merck & Co's Position In Pharmaceuticals Industry Compared To Competitors
Merck & Co makes pharmaceutical products to treat several conditions. The firm's immuno-oncology platform is growing as a major contributor to its sales. Merck and Co is in the Pharmaceuticals industry. The company is undervalued compared to its peers in the industry.
Benzinga · 1d ago
Looking Into Merck & Co's Recent Short Interest
Merck & Co's short percent of float has fallen 15.38% since its last report. The company has 19.59 million shares sold short, which is 0.77% of all regular shares available for trading. Short interest is the number of shares that have been sold short but have not been covered. Short selling is when a trader sells shares with the hope that the price will fall.
Benzinga · 1d ago
Baron Health Care Fund Q1 2024 Shareholder Letter
Baron Health Care Fund advanced 8.92% in the quarter ended March 31, 2024. The Fund's performance was in line with the Russell 3000 Health Care Index and the S&P 500 Index. Investments in health care equipment, pharmaceuticals, and life sciences added the most value in the period.
Seeking Alpha · 1d ago
Merck & Co Inc <MRK.N> expected to post earnings of $1.88 a share - Earnings Preview
Merck & Co Inc expected to post earnings of $1.88 a share. The company is expected to report a 4.9% increase in quarterly revenue to $15.196 billion. The mean estimate from 15 analysts is for the company to report quarterly revenue of $14.49 billion.
Reuters · 1d ago
Gilead Q1 Earnings Preview: Most Gains Wiped Out - Cause For Concern?
Gilead Sciences, Inc. Will report its Q1 2024 earnings on Thursday, April 25. GILD stock has given up most of its late-2022 gains due to sector-wide underperformance and disappointing data from the EVOKE-01 Phase 3 trial. In this earnings preview, I take a look at the pharmaceutical company's past earnings track record and share what to expect from Gilead's Q1 earnings. I also give a brief valuation update and share whether GILD is a good buy ahead of Q1.
Seeking Alpha · 1d ago
UPDATE 3-US FDA approves ImmunityBio's bladder cancer therapy
US FDA approves ImmunityBio's bladder cancer therapy to treat a type of bladder cancer. The drug is used in combination with the Bacillus Calmette-Guérin vaccine. Last year, the U.S. FDA declined clearance for the therapy. The therapy works to create long-term immunity in patients.
Reuters · 2d ago
Top high growth investment ratio stocks from each sector - GS
Goldman Sachs analysts listed the top stocks in each sector with the highest growth investment ratio. Analysts said they forecast capex and R&D growth to slow from about 10% in 2023 to about 7% in 2024. Growth investment ratio is defined as a company's capex less depreciation plus R&d as a share of its cash flow.
Seeking Alpha · 2d ago
More
Webull provides a variety of real-time MRK stock news. You can receive the latest news about Merck & Co through multiple platforms. This information may help you make smarter investment decisions.
About MRK
Merck & Co., Inc. is a global health care company. It offers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company’s Pharmaceutical segment includes human health pharmaceuticals and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. It sells these human health pharmaceutical products to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, and health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. The Company’s lead candidate, MK-6070, is a T-cell engager targeting delta-like ligand 3 (DLL3), an inhibitory canonical Notch ligand.